Theravance Biopharma - TBPH Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Theravance Biopharma in the last twelve months. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TBPH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TBPH, but not buy additional shares or sell existing shares.
View TBPH analyst ratings or view top-rated stocks.

3 Wall Street research analysts have issued 12 month target prices for Theravance Biopharma's stock. Their TBPH share price forecasts range from $11.00 to $19.00. On average, they expect the company's stock price to reach $14.67 in the next twelve months. This suggests a possible upside of 36.8% from the stock's current price.
View analysts price targets for TBPH or view top-rated stocks among Wall Street analysts.

Theravance Biopharma's stock was trading at $11.22 at the beginning of 2023. Since then, TBPH stock has decreased by 4.5% and is now trading at $10.72.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our TBPH earnings forecast.

Theravance Biopharma, Inc. (NASDAQ:TBPH) released its quarterly earnings results on Monday, November, 7th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.01. The biopharmaceutical company had revenue of $12.45 million for the quarter, compared to analysts' expectations of $19.09 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Theravance Biopharma investors own include Gilead Sciences (GILD), Bausch Health Companies (BHC), Exelixis (EXEL), SCYNEXIS (SCYX), Teva Pharmaceutical Industries (TEVA), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Idera Pharmaceuticals (IDRA), Pfizer (PFE) and TG Therapeutics (TGTX).

Theravance Biopharma trades on the NASDAQ under the ticker symbol "TBPH."

Theravance Biopharma's stock is owned by many different retail and institutional investors. Top institutional investors include Palliser Capital UK Ltd (0.14%), Strs Ohio (0.02%), SG Americas Securities LLC (0.02%), Allspring Global Investments Holdings LLC (0.02%), Gladius Capital Management LP (0.01%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Brett K Haumann, Philip D Worboys, Rhonda Farnum, Richard A Graham and Rick E Winningham.
View institutional ownership trends.

Shares of TBPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TBPH stock can currently be purchased for approximately $10.72.

Theravance Biopharma (NASDAQ:TBPH) has a market capitalization of $722.21 million and generates $55.31 million in revenue each year. The biopharmaceutical company earns $-199,430,000.00 in net income (profit) each year or $11.26 on an earnings per share basis.

The company employs 359 workers across the globe.

Theravance Biopharma's mailing address is UGLAND HOUSE SOUTH CHURCH STREET, GEORGE TOWN E9, KY1-1104. The official website for the company is www.theravance.com. The biopharmaceutical company can be reached via phone at (650) 808-6000 or via email at investor.relations@theravance.com.